Physician profile
Bailey Mcneese
NPI 1528517844
$737.05
in general payments reported to CMS, 2019-2025
15 companies · $16.31 in 2025
The $16.31 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $388 · 2022: $131 · 2023: $164 · 2024: $37.16 · 2025: $16.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $114.33 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $105.73 | 2021-2023 | Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.48 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.24 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $75.03 | 2021 | |
| Abbvie INC. | $64.71 | 2021-2022 | |
| Glaxosmithkline, LLC. | $38.94 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $31.77 | 2021-2023 | Breztri |
| Boston Scientific Corporation | $23.76 | 2023 | Watchman Flx |
| Sanofi Pasteur INC. | $19.43 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.33 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.10 | 2021 | |
| Pfizer INC. | $14.58 | 2021 | |
| Esperion Therapeutics, INC. | $13.49 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Mcneese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.